Amylyx Pharmaceuticals (AMLX) Current Assets: 2021-2025
Historic Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $353.4 million.
- Amylyx Pharmaceuticals' Current Assets rose 44.08% to $353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year increase of 44.08%. This contributed to the annual value of $189.4 million for FY2024, which is 59.23% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Current Assets of $353.4 million as of Q3 2025, which was up 89.09% from $186.9 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Current Assets registered a high of $464.7 million during Q4 2023, and its lowest value of $105.0 million during Q4 2021.
- Over the past 3 years, Amylyx Pharmaceuticals' median Current Assets value was $353.4 million (recorded in 2025), while the average stood at $331.2 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Current Assets spiked by 264.11% in 2022 and then slumped by 59.23% in 2024.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Current Assets stood at $105.0 million in 2021, then surged by 264.11% to $382.1 million in 2022, then climbed by 21.60% to $464.7 million in 2023, then crashed by 59.23% to $189.4 million in 2024, then skyrocketed by 44.08% to $353.4 million in 2025.
- Its Current Assets was $353.4 million in Q3 2025, compared to $186.9 million in Q2 2025 and $216.1 million in Q1 2025.